TABLE 3.
Associations Between HIV Prevention and Care Outcomes, HIV Prevalence, and Injection Drug Use Among Transgender Women—NHBS-Trans, 7 US Cities, 2019–2020
| Injected Drugs, p12m | ||||
|---|---|---|---|---|
| No | Yes | |||
| n (col%)* | n (col %)* | Adjusted Models aPR (95% CI) | P | |
| Self-reported HIV negative (N = 954)† | ||||
| Had an HIV test, past 12 mo | ||||
| No | 156 (17.4) | 8 (16.0) | NA | NA |
| Yes | 743 (82.7) | 42 (84.0) | 0.99 (0.86 to 1.17) | 0.993 |
| Aware of PrEP | ||||
| No | 71 (8.3) | 3 (6.7) | NA | NA |
| Yes | 784 (91.7) | 42 (93.3) | 1.00 (0.91 to 1.11) | 0.931 |
| Used PrEP, past 12 mo | ||||
| No | 582 (68.1) | 30 (66.7) | NA | NA |
| Yes | 273 (31.9) | 15 (33.3) | 1.06 (0.72 to 1.55) | 0.777 |
| Self-reported HIV positive (N = 606)† | ||||
| Recent HIV care visit within past 6 mo | ||||
| No | 47 (8.6) | 6 (11.3) | NA | NA |
| Yes | 497 (91.4) | 47 (88.7) | 0.99 (0.90 to 1.09) | 0.867 |
| Currently on ART | ||||
| No | 37 (6.8) | 13 (24.5) | NA | NA |
| Yes | 507 (93.2) | 40 (75.5) | 0.82 (0.72 to 0.95) | 0.007 |
| NHBS test result (HIV prevalence, N = 1561)‡ | ||||
| HIV negative | 856 (58.9) | 45 (43.3) | NA | NA |
| HIV positive | 587 (41.1) | 59 (56.7) | 1.46 (1.22 to 1.75) | <0.001 |
*
N’s do not include missing values. Percentages may not add up to 100% because of rounding.
†
Models adjusted for age, race, current health insurance, MSA, and network size. aPRs compare the row outcome by column. The referent group in this table is “no injection drug use, p12m.”
‡
Models adjusted for age, race, MSA, and network size. aPRs compare the row outcome by column. The referent group in this table is “no injection drug use, p12m.”
p12m, past 12 months; NA, not analyzed.